Skip to search formSkip to main contentSkip to account menu

30 ML eculizumab 10 MG/ML Injection [Soliris]

Known as: 30 ML Soliris 10 MG/ML Injection, Soliris 300 MG per 30 ML Injection, Soliris 300 MG in 30 ML Injection 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (2)

30 ML eculizumab 10 MG/ML Injectioneculizumab Injection [Soliris]
InjectionPolysorbate 80Sodium ChlorideSodium Phosphate, Dibasic

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Analytical comparison of Soliris® and its biosimilar, PRK-001
Soliris® (Eculizumab) was approved by regulatory authorities as the first drag for treatment of orphan disease, paroxysmal… 
2019
2019
New Data Highlighting Long-Term Efficacy and Safety Outcomes of PNH Patients Treated with Soliris® Reported at ASH Annual Meeting
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of new data… 
2018
2018
Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab ( Soliris ® ) in Patients with Refractory Generalized Myasthenia Gravis ( gMG ) Release
  • 2018
  • Corpus ID: 52239511
NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced topline results from the REGAIN… 
2018
2018
Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)
  • 2018
  • Corpus ID: 53454990
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that researchers presented data… 
Review
2015
Review
2015
Coversin Blocked in Vitro Hemolysis in an Eculizumab-Resistant PNH Patient with the C5 Polymorphism (c.2654G>A)
Background: Paroxysmal Nocturnal Hemoglobinurea (PNH) is a rare stem cell disease caused by the expansion of PIGA mutated clone(s… 
2015
2015
Tendances temporelles de l’utilisation hors indications de l’autorisation de mise sur le marche (AMM) de l’éculizumab (SOLIRIS®) et étude de l’impact des publications
2014
2014
Increased understanding of atypical haemolytic uraemic syndrome (aHUS): characteristics of patients recruited into the global aHUS registry
• Plasma exchange and infusion (PE/PI) has been the treatment of choice for aHUS;3 however, evidence suggests that PE/PI only… 
2014
2014
Safety and efficacy of eculizumab in pediatric patients with aHUS, with or without baseline dialysis
• Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by chronic, uncontrolled complement activation and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)